Clinical trials: Methotrexate
Leukemia
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
The goal of this clinical research study is to compare the effect of adding either alemtuzumab or tocilizumab to the drug combination of etoposide and dexamethasone in controlling HLH.
- Trial name
- NCT02385110
- Testing
- Alemtuzumab, Etoposide, Dexamethasone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Rheumatoid Arthritis
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not…
- Trial name
- NCT00048568
- Testing
- Abatacept, Methotrexate
- Where
- 48 sites in United States
- Volunteers
- 1,250 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)
This single arm study will investigate the pattern of B cell depletion in synovial tissue and peripheral blood of patients with active RA, after MabThera (1000mg iv x 2 on days 1 and 15) + methotrexate (10-25mg/week po)…
- Trial name
- NCT00422942
- Testing
- rituximab [MabThera/Rituxan], Methotrexate
- Where
- Netherlands
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders
This study is a pilot, proof of concept study to determine the effects of administering an oral short-chain fatty acid (SCFA) supplement to Rheumatoid Arthritis (RA) patients with inadequate response to methotrexate (MTX).
- Trial name
- EASi-RAIR (NCT05718583)
- Testing
- Butyrate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Rheumatoid Arthritis
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
This is a study of the overall safety, tolerability, and pharmacokinetics (PK) of MK-8808 versus rituximab (MabThera® and Rituxan®) in participants with moderate to severe RA with an inadequate response or intolerance to…
- Trial name
- NCT01390441
- Testing
- MK-8808, MabThera® (rituximab), Methotrexate
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC